Head-to-head · Cost-Efficiency Index
Zeuss vs Curve
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Zeuss
Patients already stable on a maintenance GLP-1 dose who want to pay per fill instead of a subscription.
Visit ZeussCurve
Cost-first shoppers who want legitScript-certified compounded GLP-1 at flat per-dose pricing.
Visit CurveThe verdict
Zeuss and Curve tie on the Cost-Efficiency Index at 63/100, so neither wins outright on the numbers. For most shoppers we'd start with Zeuss (ranked #186, a hair above #192) — Patients already stable on a maintenance GLP-1 dose who want to pay per fill instead of a subscription. But Curve is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Zeuss.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Zeuss | Curve |
|---|---|---|
| Cost-Efficiency Index | 63/100 | 63/100 |
| Semaglutide / mo | $125/mo (starting dose, compounded) | $175/mo (compounded) |
| Tirzepatide / mo | $175/mo (starting dose, compounded) | $225/mo (compounded) |
| Semaglutide / yr (modeled) | $1,500 | $2,100 |
| Tirzepatide / yr (modeled) | $2,100 | $2,700 |
| Coverage | Coverage not published | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #186 | #192 |
Zeuss
63/100Where the value is
- Genuinely no-subscription billing confirmed in its own FAQ ('no recurring charges or automatic refills') — patients pay per order, not a locked recurring plan
- LegitScript certified, with the badge and verification link displayed on the homepage
- States it 'partners exclusively with 503A and 503B state-licensed compounding pharmacies'
The tradeoffs
- Both $125 and $175 are 'starting at' prices with no disclosed dose (mg) or confirmation the price holds at higher/titrated doses
- No compounding pharmacy is named, only 'licensed partner pharmacy'
Regulatory note: the FDA issued a warning letter to Zeuss LLC dba Zeuss in February 2026. We still list and link to Zeuss; you should know the letter is on the public record before you decide.
Curve
63/100Where the value is
- Offers both compounded semaglutide and tirzepatide, with every dose priced the same so cost does not rise as you titrate up.
- LegitScript-certified (seal #51079066) and names both its 503A compounding pharmacy, VialsRx, and its provider network, Beluga Health.
- Transparent tiered pricing with a real month-to-month option; consultation, medication, and free expedited shipping included, no membership.
The tradeoffs
- Very new (2026 launch) with a thin track record; the site still shows a Webflow template credit and a leftover Cora reference in its Terms.
- The cheapest headline rates ($99 semaglutide / $135 tirzepatide) require a 12-month prepay; true month-to-month is $175 and $225.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.